Moderately to Severely Active Crohn's Disease
Drug | Drug Name | Drug Description |
---|---|---|
DB00051 | Adalimumab | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
DB00065 | Infliximab | A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
DB15091 | Upadacitinib | An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. |
DB09033 | Vedolizumab | An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB08904 | Certolizumab pegol | 3 | Completed | 1 |
DB09033 | Vedolizumab | 4 | Not Yet Recruiting | 1 |